Bluebird Bio Inc (BLUE)

[Frankestin]

The whole wallet is largely green!
Only NVIV (understandable) and BLUE (incomprehensible) are red!

I never thought I'd rack up today after the news!

In BLUE my average price is $ 28 after today!
You have to sell a lot more to scare me!

[Frankestin]

Whoever sells this now is just a damn jerk!
I SCOOOP EM

[Frankestin]

Remember that the FDA loves those who submit as BLUE!

Very diligent

[Frankestin]

WE WANT TO SEE A BEAUTIFUL SHORT SQUIZEEEEEE BIDDA in yourASS
BUAHAHAHAHAHAAHHAAHAHHAAHAHAHAHHAHA

[Frankestin]

SCOOOPEM
ALL YOU CAN BUY!

[Frankestin]

I got to 1000!

[Frankestin]

But who's the jerk selling?

[Frankestin]

CRSP $86 B
BLUE $2 B (1 B cash)
Who is undervalue?

[Frankestin]

On June 7, 2021, bluebird bio, Inc. (the "Company" or "bluebird") issued a press release to announce that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy (beti-cel; licensed as ZYNTEGLO™ in the European Union and the United Kingdom) for adult, adolescent and pediatric patients with transfusion-dependent ß-thalassemia (TDT). The Company is working closely with study investigators and clinical trial sites to resume all study activities as soon as possible.

[Frankestin]

here we go!
anyhow
I am not selling my shares under $ 50!
Fill the gap!
BIG

[jondoeuk]

The company has shown that an 'armed' OV boosts the efficacy of its CAR-T therapy (preclinical). The study assessed the effect of BLUE's anti-EGFR CAR-T cells in combo with OVs development by PsiOxus Therapeutics https://psioxus.com/wp-content/uploads/2021/04/AACR2021_Poster_Mar2021.pdf

[Frankestin]

I think the toxic securities are those of the banks and not BLUE!
Now you understand why they pumped for the banking sector!
unbelievable!
I don't sell BLUE, I keep them tight!

[Frankestin]

fair value 40/45$!
1,3b cash

Why does is not so positive for BMY?

Because the approval took place in the US which is blue's market
and
As part of the Celgene-Bristol Myers deal, Celgene shareholders would have received a $ 9 per share payment if three of Celgene's top pipeline assets were approved by certain dates.

[Frankestin]

distressed shorts!
Did Archegos Capital buy Blue?
You'd like it!
Who sells now is either a shit or a jerk!

[stocksrising]

Newsletter view hits the main driver of Future gains from Lenti study: “ The SCD patient population tends to have a higher overall risk of developing cancers, especially those involving the blood such as AML. There is a ‘CHANCE’ that the patient developed AML independent of the treatment, which would be a best-case scenario for investors. That said, the company has mentioned that the LentiGlobin vector was present in the AML cells, so further investigation is needed”.

[Coppatop]

Thinking about jumping in here, hard not to invest in GME instead at the moment though. I believe in this company long term though, been following them for a while, just haven't jumped in yet. This price range seems like historic lows for this company.

[stocksrising]

Yes Sir, but the Oncology sub once spun out

[KOGT]

As in a buyout

[stocksrising]

I still believe B*M*Y takes them out @ triple figures!

[KOGT]

Hopefully that was floor

[KOGT]

Take 2

[KOGT]

Clouds are thinning out

[rivervalley]

I was familiar with the ticker over the last several yrs but never traded it because I usually just trade penny bios that are $1-$5 range. It has been dropping for the last 2 yrs so I thought maybe a nice bounce could happen. We'll see.

[stocksrising]

Ditto, guess now will do 26-25’s at this pace..if one loved it at $100, well....lol

[rivervalley]

bought twice, in the 29's and 27's so far.

[wavetrader8x]

I'm in. This will be back at $100 within a year.

[Frankestin]

Ah how you tempt me!
I m in

[stocksrising]

Anybody else buying down here?

[Babubd]

Slapping asks and holding for $0.25-0.50++ per share. $BLUE

[Fress]

Cathie Wood likes some cutting edge Gene editing stocks.

bought some Blue at $40.00

Genome Stocks-Gene Editing.
$BEAM 5 billion market cap ARKG ETF
$EDIT 5.1 billion market cap ARKG ETF
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders ARKG ETF


$BLUE

[kylumberjack]

Anyone still alive here? Retrace to 55!

[Moose412]

Two big buys at close today, equal in size, of 86,xxx @ 53.91. That's almost $10mm. Largest sale was only 48,xxx shares.

4:1 looks long to me.

[jondoeuk]

Does anyone know anything about the UNC CAR Collaboration? Thanks

[TFMG]

Huge volatility expected in Bluebird Bio on Trial Data Release

The options market is expecting huge moves tomorrow in the Bio company BLUE as the update investors on the trial data listed below. Keep strong watch there could be enormous volume in the coming days.
Phase 3 data for LentiGlobin in HGB-212 (transfusion-dependent beta thalassemia), June 14; updated Phase 1/2 data for LentiGlobin in HGB-204 (beta-thalassemia), June 14; updated Phase 3 data for LentiGlobin in HGB-207, June 14.

[shub]

Pretty fair long term bet...I took it a while back.

[noretreat]

took a flyer on this at 35. 400 is not out of the question

[Manonb]

How's that working out for you.

[Inorout]

BLUE is ROCKING!!!

[Inorout]

BLUE = Rockstar

[swallowedhook]

THANK YOU BLUE!!! You just paid ALL my winters bills in advance and now i can relax till spring while rebuilding the race car. LOVE the money this one had brought for 3 months, as well as hope for millions of sufferers! GO BLUE. $200 next stop!!

[Inoviorulez]

https://seekingalpha.com/article/4112458-bluebird-bio-achieves-favorable-interim-data-fatal-brain-disease-children

[shub]

As a sincere stockholder, not a mere trader;
I hope that we suffer no buyout.
We have serious longterm potential to make some real money.
Sit tight through the turbulence and have faith in our science.
Ideally, we can save lives and profit.

[Inorout]

Another nice move. Buyout candidate.

[noretreat]

Bluebird headed for an all-time high by year-end

[Inorout]

Great management team and great research scientists here. Some top Harvard & Tufts faculty. Expect volitility with Bluebird but it's CAR-T technology is cutting edge gene therapy. Like my last pick Kite Pharmaceuticals, I believe Bluebird is buyout candidate too. Large pharma is losing patent protection on many billion dollar drugs and gene therapy in immunology is the next new frontier in fighting cancer. If your someone who can stomach the volitility, BLUE is a good spec stock with very promising CAR-T property.

[stlogic]

This one jumping

[Inorout]

Big dollars coming into Blue today. Great management team, superb scientists, CAR-T IP is A+. As a spec stock, I rate BLUE a strong buy.

[shub]

Fire, i didn't see any investor's section or a pipeline progress listing during my quick look around their website.
Where would i find that stuff please.

[stocktrademan]

BLUE buy 97.25









normal chart




log chart

[ash111]

Trading very strong for good reasons.